All times shown are PDT (GMT-7) (San Francisco)
Displaying One Session
Satellite Channel 3
Non-Commercial Satellite
Room
Satellite Channel 3
Session Description
Adherence to prevention and treatment therapeutics, as well as uptake and retention in care are critical challenges to sustained control of the HIV epidemic. Long-acting (LA) formulations designed to support long-term adherence and simplify treatment and prevention of HIV hold the promise of less burdensome therapeutic options, individual empowerment and wellbeing enhancement. Ensuring timely access to such game-changing innovations in low- and middle-income countries (LMICs) is key to minimize global health inequities. This satellite will provide an overview of LA products development and discuss opportunities and challenges for introduction of affordable LA solutions in HIV programmes in LMICs. The panel includes community representatives, industry and researchers focused on innovation in delivery methods, international implementing agencies, intergovernmental organizations and funders.
Non-Commercial Satellite
Full Session Recording
Room
Satellite Channel 3
Non-Commercial Satellite
Welcome address
Speaker
Room
Satellite Channel 3
Non-Commercial Satellite
Setting the scene: opportunities & challenges in long-acting landscape
Room
Satellite Channel 3
Non-Commercial Satellite
Community preferences, major concerns and ideal characteristics of long-acting products
Room
Satellite Channel 3
Non-Commercial Satellite
Discussion on health care provider perspective and health systems implications
Room
Satellite Channel 3
Non-Commercial Satellite
Long-acting Cabotegravir: Leading the way in long-acting HIV prevention therapy
Speaker
Room
Satellite Channel 3
Non-Commercial Satellite
Ensuring access to monoclonal antibodies
Speaker
Room
Satellite Channel 3
Non-Commercial Satellite
Moderated discussion
Speaker
Room
Satellite Channel 3
Non-Commercial Satellite
Concluding remarks
Room
Satellite Channel 3